Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Impedimed Limited ( (AU:IPD) ) has provided an update.
Impedimed Limited announced a change in the director’s interest in securities. Director Fiona Bones acquired an additional 156,115 ordinary shares, increasing her total to 1,308,583 shares. This acquisition was part of an arrangement where shares were issued in lieu of 30% of her director fees for the quarter ending December 31, 2024. This move indicates a strategic approach by the company to align director compensation with company performance, potentially impacting stakeholder confidence positively.
More about Impedimed Limited
Impedimed Limited operates in the medical technology industry, specializing in bioimpedance spectroscopy. The company focuses on developing and selling non-invasive medical devices that measure fluid status and tissue composition, primarily for the healthcare sector.
YTD Price Performance: -2.50%
Average Trading Volume: 31,879
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $69.19M
See more data about IPD stock on TipRanks’ Stock Analysis page.
